The on-off phenomenon.
Open Access
- 1 June 1989
- journal article
- review article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 52 (Suppl) , 29-37
- https://doi.org/10.1136/jnnp.52.suppl.29
Abstract
The on-off phenomenon is an almost invariable consequence of sustained levodopa treatment in patients with Parkinson's disease. Phases of immobility and incapacity associated with depression alternate with jubilant thaws. Both pharmacokinetic and pharmacodynamic factors are involved in its pathogenesis, but evidence is presented to indicate that the importance of levodopa handling has been underestimated and that progressive reduction in the storage capacity of surviving nigrostriatal dopamine terminals is not a critical factor. Re-distribution of levodopa dosage which may mean smaller, more frequent doses, or larger less frequent increments, may be helpful in controlling oscillations in some patients. Dietary protein restriction, the use of selegiline hydrochloride and bromocriptine may also temporarily improve motor fluctuations. New approaches to management include the use of subcutaneous apomorphine, controlled-release preparations of levodopa with a peripheral dopa decarboxylase inhibitor and the continuous intra-duodenal administration of levodopa.Keywords
This publication has 48 references indexed in Scilit:
- SUBCUTANEOUS APOMORPHINE FOR ON-OFF OSCILLATIONS IN PARKINSON'S DISEASEThe Lancet, 1988
- Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonismAnnals of Neurology, 1988
- SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASEThe Lancet, 1988
- Treatment of Motor Fluctuations in Parkinsonʼs Disease with an Oral Sustained-Release Preparation of L-DopaClinical Neuropharmacology, 1986
- Dopamine D2 receptor density remains constant in treated Parkinson's diseaseAnnals of Neurology, 1986
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984
- Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)Acta Neurologica Scandinavica, 1983
- Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.Journal of Neurology, Neurosurgery & Psychiatry, 1975
- Variability of L-Dopa Absorption in ManAustralian and New Zealand Journal of Medicine, 1974
- VALUE OF PLASMA-DOPA DETERMINATIONS IN THE MANAGEMENT OF PARKINSON'S DISEASEThe Lancet, 1973